reports
Moody's Ratings affirms Astellas' A3 rating; outlook remains stable
Moody's Ratings (Moody's) has affirmed Astellas Pharma Inc.'s A3 issuer rating. The outlook remains stable. "The affirmation of Astellas' A3 rating reflects our expectation that Astellas' leverage will continue improving, with debt/EBITDA falling below 2x over the next 12–18 months due to debt rep...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Astellas Pharma Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 14 November 2024 in which we reassessed the appropriateness of the ratings in the cont...
Moody's affirms Astellas' A3 rating; outlook stable
Moody's Japan K.K. has affirmed Astellas Pharma Inc.'s A3 issuer rating. The outlook remains stable. "The affirmation reflects our expectation that the company will deleverage over the next two years following its $5.9 billion debt-funded acquisition of Iveric bio, Inc." says Dean Enjo, a Moody'...
Moody's affirms Astellas' A3 rating; outlook stable (Japanese)
Contact:東京 東京円城 ディーン セメトコ 真理子主任格付アナリスト／VP シニア・アナリスト 格付責任者／SVP マネージャーコーポレート・ファイナンス・グループ コーポレート・ファイナンス・グループムーディーズ・ジャパン株式会社 ムーディーズ・ジャパン株式会社お客様専用電話番号：03-5408-4100報道関係者電話番号：03-5408-4110お客様専用電話番号：03-5408-4100報道関係者電話番号：03-5408-4110[MJKK]アステラス製薬の格付 A3 を確認、見通しは安定的2023 年 5 月 10 日、東京、ムーディーズ・ジャパン株式会社（以下「ムーディーズ」...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.